Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
ChemSex and HCV transmission among UK MSM

A recently published guide for health professionals (ChemSex & Hepatitis C), claiming to be based on c.500 conversations with MSM clients, offers an illuminating, ground-level account of one risk environment: events involving “ChemSex”, or the collective use of recreational drugs to enhance sexual experience. The authors claim that ChemSex parties are a growing HCV risk for MSM for three reasons: greater availability of certain non-injection drugs; increased injecting drug use; more widespread use of smartphone Apps and online “hooking-up” sites.

Published
03 February 2015
From
BMJ Group blogs
Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries

Activist Strategies for Increasing Access to HCV Treatment in Low- and Middle-Income Countries presents a number of key strategies through real-world case studies and shows how strategies used to combat the AIDS epidemic can be—and have been—adapted to increase HCV treatment access.

Published
03 February 2015
From
TAG
AbbVie Inc stock drops after expectations for Viekira Pak fall short

AbbVie shares fell 4.4% after market gathered from the company’s forecast that the new hepatitis C treatment may bring in just $2 billion in 2015, falling short of the high expectations.

Published
02 February 2015
From
Bidness Etc
AbbVie next-generation hepatitis C drugs look promising in early studies

AbbVie's investigational HCV protease inhibitor ABT-493 and NS5A inhibitor ABT-530 demonstrated good antiviral activity in patients with genotype 1 chronic hepatitis C in a three-day monotherapy study, as

Published
30 January 2015
By
Liz Highleyman
Hepatitis C drug access: Europe is the new Africa

The remarkably high cure rates being reported with the newest hepatitis C drugs are only likely to be used by a tiny percentage of people who need them.

Published
30 January 2015
From
HIV i-Base
Petition: Equitable access to HCV drugs

We, the undersigned, are organizations of people living with hepatitis C virus (HCV), HIV, and our allies. We believe in equitable access to life-saving treatment for all who need it. We write to express our indignation over Gilead’s pricing and licensing policies for the HCV drug, sofosbuvir.

Published
30 January 2015
From
Petitionbuzz
MSF response to Gilead announcement on inclusion of hepatitis C drug GS-5816 in voluntary licence

GS-5816 is an important anti-hepatitis C compound that, in combination with sofosbuvir, will greatly simplify treatment for developing countries. However, it appears that none of the terms and conditions of the original licence agreement has been changed, meaning that the concerns that MSF has with the licence agreement remain, including the limited geographic scope of the agreement, restrictions on the production and export of active pharmaceutical ingredient, and the inclusion of an ethically and medically controversial and problematic anti-diversion clause.

Published
27 January 2015
From
Médecins Sans Frontières press release
Gilead Expands Hepatitis C Generic Licensing Agreements to Include Investigational Pan-Genotypic Agent

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company has expanded its hepatitis C generic licensing agreements to include the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase 3 clinical studies as part of a single tablet regimen that combines the compound and sofosbuvir for the treatment of all six genotypes of hepatitis C. The expanded agreements will allow Gilead’s India-based partners to manufacture GS-5816 and the single tablet regimen of sofosbuvir/GS-5816, once approved, for distribution in 91 developing countries, which together account for 54 percent of the total worldwide population of individuals infected with the hepatitis C virus (HCV).

Published
27 January 2015
From
Gilead press release
German insurers win discounts on Gilead's Sovaldi

The head of Gilead's German operations told the magazine that discounts from the list price of 60,000 euros (44,867 pounds) per treatment had been negotiated with four of Germany's statutory health insurers but declined to give the size of the discounts.

Published
26 January 2015
From
Yahoo News
Merck discontinues Victrelis (boceprevir) voluntarily in the United States

Merck has decided to voluntarily discontinue the manufacture and distribution of Victrelis in the United States by December 2015.

Published
21 January 2015
From
EATG

Filter by country